Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (vol 386, pg 1537, 2015)

被引：0
|
作者：
Roth, D.
Nelson, D. R.
Bruchfeld, A.
机构：
来源：
LANCET | 2015年 / 386卷 / 10006期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1824 / 1824
页数：1
相关论文
共 50 条
  • [21] Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis
    El Raziky, M.
    Gamil, M.
    Ashour, M. K.
    Sameea, E. A.
    Doss, W.
    Hamada, Y.
    Van Dooren, G.
    DeMasi, R.
    Keim, S.
    Lonjon-Domanec, I.
    Hammad, R.
    Hashim, M. S.
    Hassany, M.
    Waked, I.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (02) : 102 - 110
  • [22] Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India
    Shah, S. R.
    Chowdhury, A.
    Mehta, R.
    Kapoor, D.
    Duseja, A.
    Koshy, A.
    Shukla, A.
    Sood, A.
    Madan, K.
    Sud, R.
    Nijhawan, S.
    Pawan, R.
    Prasad, M.
    Kersey, K.
    Jiang, D.
    Svarovskaia, E.
    Doehle, B.
    Kanwar, B.
    Subramanian, M.
    Acharya, S. K.
    Sarin, S.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (05) : 371 - 379
  • [23] Efficacy and safety of grazoprevir plus ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection
    Gane, E.
    Ben Ari, Z.
    Mollison, L.
    Zuckerman, E.
    Bruck, R.
    Baruch, Y.
    Howe, A. Y. M.
    Wahl, J.
    Bhanja, S.
    Hwang, P.
    Zhao, Y.
    Robertson, M. N.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (10) : 789 - 797
  • [24] C-SWIFT: GRAZOPREVIR/ELBASVIR plus SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
    Poordad, F.
    Lawitz, E.
    Gutierrez, J. A.
    Evans, B.
    Howe, A.
    Feng, H. -P.
    Li, J. J.
    Hwang, P.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S192 - S193
  • [25] Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection A Randomized Trial
    Pianko, Stephen
    Flamm, Steven L.
    Shiffman, Mitchell L.
    Kumar, Sonal
    Strasser, Simone I.
    Dore, Gregory J.
    McNally, John
    Brainard, Diana M.
    Han, Lingling
    Doehle, Brian
    Mogalian, Erik
    McHutchison, John G.
    Rabinovitz, Mordechai
    Towner, William J.
    Gane, Edward J.
    Stedman, Catherine A. M.
    Reddy, K. Rajender
    Roberts, Stuart K.
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (11) : 809 - 817
  • [26] Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
    Hezode, Christophe
    Hirschfield, Gideon M.
    Ghesquiere, Wayne
    Sievert, William
    Rodriguez-Torres, Maribel
    Shafran, Stephen D.
    Thuluvath, Paul J.
    Tatum, Harvey A.
    Waked, Imam
    Esmat, Gamal
    Lawitz, Eric J.
    Rustgi, Vinod K.
    Pol, Stanislas
    Weis, Nina
    Pockros, Paul J.
    Bourliere, Marc
    Serfaty, Lawrence
    Vierling, John M.
    Fried, Michael W.
    Weiland, Ola
    Brunetto, Maurizia R.
    Everson, Gregory T.
    Zeuzem, Stefan
    Kwo, Paul Y.
    Sulkowski, Mark
    Braeu, Norbert
    Hernandez, Dennis
    McPhee, Fiona
    Wind-Rotolo, Megan
    Liu, Zhaohui
    Noviello, Stephanie
    Hughes, Eric A.
    Yin, Philip D.
    Schnittman, Steven
    GUT, 2015, 64 (06) : 948 - 956
  • [27] ADDITIONAL BOCEPREVIR INCREASES SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION
    Desai, Mitesh
    SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (05) : 449 - 449
  • [28] Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease
    Ogawa, Eiichi
    Furusyo, Norihiro
    Azuma, Koichi
    Nakamuta, Makoto
    Nomura, Hideyuki
    Dohmen, Kazufumi
    Satoh, Takeaki
    Kawano, Akira
    Koyanagi, Toshimasa
    Ooho, Aritsune
    Takahashi, Kazuhiro
    Kato, Masaki
    Shimoda, Shinji
    Kajiwara, Eiji
    Hayashi, Jun
    ANTIVIRAL RESEARCH, 2018, 159 : 143 - 152
  • [29] FINAL SVR24 DATA FROM THE PHASE 3 C-EDGE TREATMENT-NAIVE STUDY OF ELBASVIR (EBR)/GRAZOPREVIR (GZR) IN PATIENTS WITH CHRONIC HCV GENOTYPE 1, 4 OR 6 INFECTION
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P.
    Ari, Z. B.
    Zhao, Y.
    Brown, D.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    Martin, E.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S821 - S821
  • [30] Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
    Hezode, Christophe
    Asselah, Tarik
    Reddy, K. Rajender
    Hassanein, Tarek
    Berenguer, Marina
    Fleischer-Stepniewska, Katarzyna
    Marcellin, Patrick
    Hall, Coleen
    Schnell, Gretja
    Pilot-Matias, Tami
    Mobashery, Niloufar
    Redman, Rebecca
    Vilchez, Regis A.
    Pol, Stanislas
    LANCET, 2015, 385 (9986): : 2502 - 2509
12345